<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PENBUTOLOL</span><br/>(pen-bu'tol-ol)<br/><span class="topboxtradename">Levatol<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent, sympatholytic)</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic blocking agent which competes with epinephrine and norepinephrine for available beta receptor sites.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers both supine and standing BP in hypertensive patients. Hypotensive effect is associated with decreased cardiac output,
         suppressed renin activity, as well as beta blockage.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension. May be used alone or with other antihypertensive agents.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Clients with cardiogenic shock, sinus bradycardia, second and third degree AV block; bronchial asthma; hypersensitivity to
         the drug.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac failure; chronic bronchitis, emphysema; diabetes; pregnancy (category C), lactation. Safety and effectiveness in children
         is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg once/d, may increase to 4080 mg/d if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue by reducing the dose gradually over 1 to 2 wk.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, fatigue, <span class="speceff-common">headache,</span> insomnia. <span class="typehead">CV:</span> AV block, bradycardia. <span class="typehead">GI:</span> Nausea, diarrhea, dyspepsia. <span class="typehead">Respiratory:</span> Cough, dyspnea. <span class="typehead">Urogenital:</span> Impotence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">diuretics</span> and other <span class="classification">hypotensive agents</span> increase hypotensive effect; effects of <b>albuterol,</b>
<b>metaproterenol,</b>
<b>terbutaline,</b>
<b>pirbuterol,</b> and penbutolol are antagonized; <span class="classification">nsaid</span>s blunt hypotensive effect; decreases hypoglycemic effect of <b>glyburide;</b>
<b>amiodarone</b> increases risk of bradycardia and sinus arrest. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 20 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Take apical pulse before administering drug. If pulse is below 60, or other established parameter, hold the drug and contact
            physician.
         </li>
<li>Take a BP reading before giving drug, if BP is not stabilized. If systolic pressure is <img src="../images/special/lesserorequal.gif"/>90
            mm Hg, hold drug and contact physician.
         </li>
<li>Check BP near end of dosage interval or before administration of next dose to evaluate effectiveness.</li>
<li>Monitor therapeutic effectiveness. Full effectiveness of the drug may not be seen for 46 wk.</li>
<li>Watch for S&amp;S of bronchial constriction. Report promptly and withhold drug.</li>
<li>Monitor diabetics for loss of glycemic control. Drug suppresses clinical signs of hypoglycemia (e.g., BP changes, increased
            pulse rate) and may prolong hypoglycemic state.
         </li>
<li>Monitor carefully for exacerbation of angina during drug withdrawal.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not discontinue the drug without physician's advice because of the possible exacerbation of ischemic heart disease.</li>
<li>If diabetic, report persistent S&amp;S of hypoglycemia (see Appendix F) to physician (diabetics).</li>
<li>Avoid driving or other potentially hazardous activities until response to drug is known.</li>
<li>Make position changes slowly and avoid prolonged standing. Notify physician if dizziness and light-headedness persist.</li>
<li>Comply with and do not alter established regimen (i.e., do not omit, increase, or decrease dosage or change dosage interval).</li>
<li>Avoid prolonged exposure of extremities to cold.</li>
<li>Avoid excesses of alcohol. Heavy alcohol consumption [i.e., &gt;60 mL (2 oz)/d] may elevate arterial pressure; therefore, to
            maintain treatment effectiveness, either avoid alcohol or drink moderately (
         </li><li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>